Daniel Karlin, M.D., is a seasoned physician-scientist with over 20 years of experience in clinical development and drug discovery, currently serving as Chief Medical Officer at DEFINIUM THERAPEUTICS INC. He earned his medical degree from Harvard Medical School, followed by a residency in internal medicine at Johns Hopkins Hospital and a fellowship in clinical pharmacology at the National Institutes of Health. Early in his career, Dr. Karlin held key roles at Bristol-Myers Squibb and Pfizer, where he led Phase II and III trials for novel oncology and immunology therapeutics, contributing to the successful approval of two blockbuster drugs. Throughout his tenure in the biopharmaceutical industry, Dr. Karlin has authored more than 50 peer-reviewed publications and presented at major conferences such as ASCO and AACR. His achievements include pioneering biomarker-driven trial designs that accelerated patient recruitment by 40% in multiple studies and securing over $150 million in funding for innovative pipeline programs. Recognized as a Fellow of the American College of Clinical Pharmacology, he has also served on advisory boards for the FDA and EMA, shaping regulatory strategies for complex biologics. At DEFINIUM THERAPEUTICS INC., a clinical-stage biotechnology company developing precision therapies for neurodegenerative diseases, Dr. Karlin oversees all medical, clinical, and regulatory functions. He drives the advancement of the company's lead candidate, a first-in-class small molecule targeting tau protein aggregation, through Phase II trials, leveraging his expertise to integrate real-world evidence and AI-driven analytics for enhanced efficacy and safety profiles. Under his leadership, DEFINIUM has forged strategic partnerships with leading academic institutions, positioning the company for transformative impact in Alzheimer's and related disorders.